Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
Holding SMMT?
Track your performance easily
SMMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $33.89
Previous Close$29.48
Volume11.67M
Average Volume (3M)4.17M
Market Cap
$21.36B
Enterprise Value$21.28B
Total Cash (Recent Filing)$186.24M
Total Debt (Recent Filing)$106.10M
Price to Earnings (P/E)―
Beta-1.89
Next Earnings
Nov 06, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding724,537,751
10 Day Avg. Volume14,806,624
30 Day Avg. Volume4,171,720
Standard Deviation0.62
R-Squared0.00688
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)109.19
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-175.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue36.44K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-37.45
Forecast
1Y Price Target
$29.67Price Target Upside13.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Summit Therapeutics News
Ownership Overview
81.52% Insiders
2.91% Mutual Funds
6.12% Other Institutional Investors
9.45% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $1.64 and its highest was $33.89 in the past 12 months.
What is Summit Therapeutics’s market cap?
Currently, no data Available
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Aug 06, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.012.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -$0.07.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 724,537,800 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went down -4.79%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Among the largest hedge funds holding Summit Therapeutics’s share is Baker Bros Advisors LP. It holds Summit Therapeutics’s shares valued at 181M.
---
Summit Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.67 (13.16% Upside)
$29.67 (13.16% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 23.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 22.8%
Last 30 Days ▲ 52.3%
Last 30 Days ▲ 52.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1476.47%
12-Months-Change
Fundamentals
Return on Equity
-102.79%
Trailing 12-Months
Asset Growth
44.02%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
---
SMMT Earnings Call
Q2 2024
0:00 / 0:00
---
SMMT Stock 12 Month Forecast
Average Price Target
$29.67
▲(13.16% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Corbus Pharmaceuticals
―
FibroGen
―
Karyopharm Therapeutics
―
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+492.06%
reiterated a buy rating 11 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +492.06% per trade.
---